Patents Examined by Karen Cochrane Carlson
  • Patent number: 9976129
    Abstract: A fusion protein for protein detection in which are fused: a protein domain including at least one among a C1 domain of protein G, a C2 domain of protein G, and a C3 domain of protein G; and a double mutant D153G/D330N of Escherichia coli alkaline phosphatase (BAP) in which the 153 amino acid residue Asp has been substituted by Gly and the 330 amino acid residue Asp has been substituted by Asn, a double mutant D153H/D330N of Escherichia coli alkaline phosphatase (BAP) in which the 153 amino acid residue Asp has been substituted by His and the 330 amino acid residue Asp has been substituted by Asn, or a double mutant K328R/D330N of Escherichia coli alkaline phosphatase (BAP) in which the 328 amino acid residue Lys has been substituted by Arg and the 330 amino acid residue Asp has been substituted by Asn.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: May 22, 2018
    Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, Hitachi, Ltd.
    Inventors: Noriho Kamiya, Kyoichi Matsuba, Kenji Nagai, Kounosuke Hayashi
  • Patent number: 9957540
    Abstract: Methods for recombinant production of steviol glycoside and compositions containing steviol glycosides are provided herein.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 1, 2018
    Assignee: EVOLVA SA
    Inventors: Michael Dalgaard Mikkelsen, Jorgen Hansen, Ernesto Simon, Federico Brianza, Angelika Semmler, Kim Olsson, Simon Carlsen, Louis Düring, Alexei Ouspenski, Paula Hicks
  • Patent number: 9951299
    Abstract: The present invention relates to variants with cutinase activity of a parent cutinase, comprising an alteration at one or more (e.g. several) positions corresponding to positions: 36, 37, 40, 78, 90, 114, 150, 196, 216, or 217 of SEQ ID NO: 2, wherein the alteration is a substitution for positions 40, 78, 90, 114, 150, 196 and 216, and a deletion for positions 36, 37 and 217, and wherein the variant has at least 75% but less than 100% sequence identity to the mature polypeptide of SEQ ID NO: 2. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and method for obtaining and methods of producing the variants. It also relates to compositions comprising the variant, and to methods for using the variant.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: April 24, 2018
    Assignee: Novozymes A/S
    Inventors: Leonardo De Maria, Rakhi Saikia, Santhosh Vasu Mepadam, Ting Sun
  • Patent number: 9951319
    Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 24, 2018
    Assignee: Novozymes A/S
    Inventors: Sara Landvik, Lars H. Oestergaard, Lisbeth Kalum
  • Patent number: 9943858
    Abstract: The invention relates to a waste treatment method in which waste is subjected to a first screening process (4). The fraction of waste passing through the screening is subjected to a pre-fermentation treatment in a rotating tube (1) and the material leaving the pre-fermentation treatment tube is subjected to mixing in a mixing hopper, and, subsequently, to a methanization treatment in a digester (2). The organic materials are separated from the undesirable products in the material leaving the pre-fermentation treatment tube before it enters the digester. The digester (2) is horizontal and mechanically stirred, and a fraction of the digestate leaving the digester is recirculated at least in the mixing hopper, the recirculation rate being sufficiently high to ensure complete mixing.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: April 17, 2018
    Assignee: SUEZ ENVIRONMENT
    Inventor: Arnaud Sommain
  • Patent number: 9944934
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: April 17, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Patent number: 9944968
    Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 17, 2018
    Assignees: Biogen MA Inc., Samsung Bioepis
    Inventors: William Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
  • Patent number: 9938318
    Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 10, 2018
    Assignee: OCTAPHARMA AG
    Inventors: Petra Schulz, Rainer Pape, Werner Gehringer
  • Patent number: 9932389
    Abstract: A chemoembolic agent is disclosed that includes an injectable, recombinantly synthesized silk-elastin like protein copolymer and one or more chemotherapeutic agents. Upon injection, the chemoembolic agent blocks the tumor vasculature, including the capillary bed, and may optionally release chemotherapeutic agents. The chemoembolic agent may be used to treat cancer, including hepatocellular carcinoma.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: April 3, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Joseph Cappello, Hamidreza Ghandehari, Azadeh Poursaid
  • Patent number: 9934937
    Abstract: Protein layers (1) repeating regularly in two dimensions comprise protein protomers (2) which each comprise at least two monomers (5), (6) genetically fused together. The monomers (5), (6) are monomers of respective oligomer assemblies (3), (4) into which the monomers are assembled to assembly of the protein layer. The first oligomer assembly (3) belongs to a dihedral point group of order O, where O equals (3), (4) or (6) and has a set of O rotational symmetry axes of order (2). The second oligomer assembly (4) has a rotational symmetry axis of order (2). Due to the symmetry of the oligomer assemblies (3), (4), the rotational symmetry axes of each second oligomer assembly (4) is aligned with one of said set of O rotational symmetry axes of a first oligomer assembly (3) with (2) protomers being arranged symmetrically therearound.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: April 3, 2018
    Assignee: Oxford University Innovation Limited
    Inventors: John Charles Sinclair, Martin Edward Mäntylä Noble
  • Patent number: 9926546
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: March 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Patent number: 9925276
    Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 27, 2018
    Assignee: EPEIUS BIOTECHNOLOGIES CORPORATION
    Inventors: John P. Levy, Rebecca A. Reed, Joseph McNulty, Robert G. Johnson, Jr.
  • Patent number: 9920102
    Abstract: Fluorescent and non-fluorescent fusion tags derived from green fluorescent protein (GFP). The fusion tags harbor substitutions with respect to GFP that increase expression of target proteins to which the fusion tags are fused; increase solubility; prevent dimerization and oligomerization, particularly in oxidizing environments such as the endoplasmic reticulum (ER); and, in some cases, enhance fluorescence of the fusion tag itself. The substitutions include various combinations of substitutions at select cysteine residues in GFP, substitutions in or near the GFP chromophore, and/or other substitutions. The fusion tags can be used for increasing expression of target proteins for mass production thereof or as a fluorescent tag.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 20, 2018
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Erik Lee Snapp, Lindsey M. Costantini
  • Patent number: 9914945
    Abstract: Continuous processes for the anaerobic bioconversion of syngas to oxygenated hydrocarbonaceous products, in particular lower alkanols, are disclosed in which nutrients, including micronutrients, and lower carboxylate anion are recovered from at least a portion of an aqueous distillation fraction from a distillation unit operation to recover lower alkanols by using a “tight” ultrafiltration membrane. At least about 75 percent of the water permeates the ultrafiltration membrane. The tight ultrafiltration membrane rejects sufficient components that are adverse to the microorganisms used in the bioconversion that continuous fermentation operations over long durations can be achieved.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: March 13, 2018
    Assignee: Synata Bio Inc.
    Inventor: Robert Hickey
  • Patent number: 9913881
    Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: March 13, 2018
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Patent number: 9907839
    Abstract: Methods of treating glycogen storage disease type II, by administering acid ?-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 6, 2018
    Assignee: Duke University
    Inventor: Yuan-Tsong Chen
  • Patent number: 9909143
    Abstract: This disclosure describes a cell that includes an engineered subcellular compartment that generally includes a proteinaceous shell that includes at least one bacterial microcompartment (BMC) polypeptide. In some embodiments, the engineered subcellular compartment can further include one or more targeted enzymes. We further describe methods of making and using such cells.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: March 6, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Claudia Margarete Schmidt-Dannert, Swati Choudhary Saurkar, Maureen Blacker Quin, Mark Anton Held
  • Patent number: 9901626
    Abstract: A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: February 27, 2018
    Inventor: G. Blair Lamb
  • Patent number: 9902977
    Abstract: Disclosed herein is a bioenergy production system with reduced carbon dioxide emissions and process wastes; including a process for producing a bioalcohol and a biogas by subjecting a biomass, such as: herbaceous and woody plants, fruit pulp, freshwater and sea algae, grains, aerobic and anaerobic sludge, saccharides, polyols and carbohydrates, to a combined process of a biosaccharification/alcohol fermentation, including a biomass pretreatment process; and a process for producing a methane biogas with a reduced level of carbon dioxide and hydrogen sulfide, via an algae cultivation process with a view to purifying the carbon dioxide and hydrogen sulfide contained in the biogas; wherein, when the algae to be cultivated is microalgae, biodiesel is produced by subjecting the harvested microalgae to a biodiesel manufacturing process while recycling the glycerol and the saccharide-containing waste produced as byproducts to the biosaccharification/alcohol fermentation process, and when the algae to be cultivated is
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: February 27, 2018
    Assignees: INDUSTRY ACADEMIC COOPERATION FOUNDATION. DAEGU UNIVERSITY, MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY
    Inventors: Kwang-Hee Lim, Kisay Lee, Young-Soon Um, Min-Woo Lee
  • Patent number: 9902984
    Abstract: The present application discloses a method of making a mixture of 2?-FL and DFL in high yield by culturing, with lactose, a genetically modified cell having a recombinant gene that encodes a single fucosyl transferase. The resulting mixture of 2?-FL and DFL can be subjected to hydrolysis initiated by an acid or mediated by a fucosidase to produce fucose in high yields.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: February 27, 2018
    Assignee: GLYCOM A/S
    Inventors: Gyula Dekany, Pauline Peltier-Pain, Dóra Molnár-Gábor, Markus Hederos